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Abstract The epidemiology of multiple sclerosis (MS) is
rapidly changing in many parts of the world. Based on the
Kurtzke classification, the Arabian Gulf Region is located
in a low-risk zone for MS; however, recent studies suggest
a moderate-to-high prevalence nearby (31–55 MS per
10,0000 individuals), with an increase in incidence in
recent years. The relapsing-remitting disease course ratio is
2.5:1 versus the primary progressive type. In a geographic
area that was previously associated with low prevalence;
the recent high prevalence and fast rising incidence of MS
in the gulf countries, encouraged the neurologists of this
region to meet in a consensus panel, in order to share our
latest findings in terms of MS epidemiology and consent on
MS management in the Arabian Gulf. Therefore 20 key
opinion leader neurologists and MS experts representing
various countries of the Arabian Gulf have met in Dubai on
the 2 and 3 February 2012, they shared their latest epide-
miological findings, discussed recent MS aspects in the
region, and consented on MS management relevantly to
this geographic area.
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Epidemiology of MS in the region
There are relatively few studies regarding epidemiology of
MS in this region [1]. In 1988, Yaqub et al. [2] published a
paper about MS in Saudi Arabia, stating that there are
indications of increasing incidence of MS in Saudi Arabia.
They noted that the symptomatology of MS and the site of
lesions are similar to that seen in the West, but the course
and evolution might be different.
Ten years later, Daif et al. [3] published another paper
about the pattern of presentation of multiple sclerosis (MS)
in Saudi Arabia, stating also that it resembles the western
type of MS.
In an unpublished communication, Prof. Bohlega esti-
mated the prevalence of MS in Saudis to be 40/100,000 in
2008. ‘‘Although it used to be thought that MS is not
common in Saudi Arabia, it is now clear that it is fairly
prevalent, under-diagnosed and in increase’’, stated Prof.
Bohlega.
In their retrospective study in 2005, Alshubaili et al. [1]
examined the changes in incidence and prevalence of MS
in Kuwait. The total incidence rate increased from 1.05/
100,000 population in 1993 to 2.62/100,000 in 2000. The
increased incidence of MS was most pronounced among
Kuwaiti women (from 2.26/100,000 in 1993 to 7.79/
100,000 in 2000. The total prevalence rate increased from
6.68/100,000 in 1993 to 14.77/100,000 in 2000. It was
much higher for Kuwaitis (31.15/100,000), as compared to
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non-Kuwaitis (5.55/100,000), in a complete reversal of the
pattern observed before 1990. The prevalence was also
higher among Kuwaiti women (35.54/100,000), as com-
pared with Kuwaiti men (26.65/100,000). In conclusion,
the incidence and prevalence of MS in Kuwait has
increased between the early and late 1990s with no signs of
leveling off.
In a recent paper in 2011, Inshasi and Thakre [4]
determined the prevalence of MS in Dubai (UAE). They
found the prevalence to be 54.77/100,000 in 2007 which
was surprisingly high. There were no previous studies to
compare to it. They concluded that Dubai should be con-
sidered as one of the regions with medium to high risk of
MS, with a prevalence rate higher than what has been
previously believed.
So, why is MS prevalence increasing?
Several hypotheses attempt to answer this question but
none of them is proven. Is it the increase in the young
population? Is it the change in lifestyle of this region, with
the introduction of the air-conditioning systems in the
region? Is it the vitamin D deficiency?
In fact, vitamin D deficiency has been recently noted in
the Gulf region despite the area’s sunny climate. Although
our countries have a sunny environment, vitamin D defi-
ciency is one of the main public health problems. Studies in
Saudi Arabia revealed that 28 to 80 % of adults had vita-
min D deficiency [5].
Is it consanguinity? Knowing that, in the Arabian Gulf
countries every other marriage is consanguineous, in 2011
Al Jumah et al. [6, 7] correlated the prevalence of familial
multiple sclerosis (FMS) and rate of parental consanguinity
(PC). He concluded that MS patients with a history of PC
were more likely to have FMS, suggesting a potential role
of consanguinity.
With lack of official registries and published studies in
some countries concerning the epidemiology of MS in the
region, a central MS registry and long term follow-up
epidemiological studies are recommended [4].
MS management in the Arabian Gulf countries
Diagnosis
Successful management of MS requires early intervention.
Knowing that, permanent axonal loss begins before MS is
diagnosed, and treatment is more effective in the inflam-
matory stage, when there are more intact axons to protect.
And the famous quote ‘‘delaying treatment in MS: what is
lost is not regained’’ is always true [8]. Therefore, early
intervention requires early diagnosis, and the 2010
McDonald criteria promote early diagnosis. And we neu-
rologists of this region use the McDonald 2010 criteria for
diagnosing MS, adding complementary tests to rule out
other likely diagnosis of vasculitis, Behcet disease, bru-
cellosis and B12 deficiency which are more prevalent in
our countries than in the western countries.
We agree that MRI is the best imaging technology for
detecting the presence of MS plaques or lesions in different
parts of the CNS. However, the diagnosis of MS cannot be
made solely on the basis of the MRI, the patient’s medical
history and the neurologic exam can provide enough evi-
dence to meet the diagnostic criteria. Cerebrospinal fluid
analysis is less used because the patients are usually
reluctant to undergo a lumbar puncture.
We would like to emphasize that the diagnosis of MS
should be made by a neurologist and not by other spe-
cialists as it is common in our region. And therefore, after
the diagnosis of MS is established, we recommend that the
patient should be regularly followed-up by an expert neu-
rologist, more frequently after the early phase of diagnosis.
Treatment
Several therapies for MS exist, although there is no known
cure. The most common initial course of the disease is the
relapsing-remitting subtype.
As with any medical treatment, medications used in the
management of MS may have several adverse effects, and
many possible therapies are still under investigation. At the
same time, different alternative treatments are pursued by
many patients, despite the paucity of supporting, compara-
ble, replicated scientific study. We state here the Zamboni
liberation procedure is not an option for MS treatment.
Disease-modifying treatments
As of 2012, six disease-modifying treatments have been
approved by regulatory agencies of different countries,
including the U.S. Food and Drug Administration (FDA)
and the European Medicines Agency (EMA). The six drugs
are interferon beta-1a (Avonex, Rebif), interferon beta-1b
(Betaferon, Extavia), glatiramer acetate (Copaxone),
mitoxantrone (Novantrone), natalizumab (Tysabri) and
fingolimod (Gilenya), the first oral drug available. In our
region all interferons are available for the treatment of MS.
The aim of starting disease-modifying treatment is to
control relapses, to slow the accumulation of the disease on
MRI, the disability progression, and finally to improve the
quality of life of the patient.
Clinically isolated syndrome (CIS)
The earliest clinical presentation of relapsing-remitting MS
(RRMS) is the clinically isolated syndrome (CIS), i.e., a
single attack of a single symptom. During a CIS, there is a
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subacute attack suggestive of demyelination but the patient
does not fulfill the criteria for diagnosis of MS [9]. Several
studies have shown that early treatment of CIS after the
initial presentation can delay the development of clinically
definite multiple sclerosis (CDMS). These results support
the use of interferon after a first clinical demyelinating
event and indicate that there may be beneficial effects of
immediate treatment compared with delayed initiation of
treatment [10–12]. Therefore, we agree that patients who
present with CIS should be treated. However, CIS patients
who do not wish to start treatment should be followed up
by MRI at 3 month intervals. It should be stated that many
cases of CIS are reclassified as definite MS, according to
final amendment of McDonald Criteria 2010, and should be
treated accordingly. Therefore, all neurologists at this
meeting support early initiation of IFNb therapy in patients
with CIS in view of the supportive data and its availability
in the region. However, in CIS patients with normal or few
lesions on brain MRI and especially those with monofocal
symptoms and complete recovery, a brief watchful phase
with a follow up brain MRI at 3–6 months is appropriate.
Also recently glatiramer (trade name Copaxone) has been
shown to be beneficial after a first clinical demyelinating
event; however Copaxone is unavailable in our region [13].
Relapsing-remitting MS (RRMS)
The two approved interferons are the interferon beta-1a
(with two commercial formulations, with trade names
Avonex and Rebif; the first injected weekly, the latter three
times a week), and the interferon beta-1b (trade name
Betaferon, Extavia), injected every other day.
The other approved drugs are glatiramer acetate or
Copaxone, injected daily, which is a mixture of polypep-
tides which may protect important myelin basic proteins by
substituting itself as the target of immune system attack
[14]. We note here, that Copaxone is not available in our
region. Mitoxantrone is an immunosuppressant also used in
cancer chemotherapy. Natalizumab, marketed as Tysabri is
a monoclonal antibody and finally fingolimod (trade name
Gilenya) is a sphingosine-1-phosphate receptor modulator.
Mitoxantrone use is limited by severe cardiotoxicity,
and it is not considered as a long-term therapy. Recent data
show higher risk of leukemia, almost to exclude its use
in RRMS in the presence of fingolimod and natalizumab
[15, 16].
Worth noting, that neither fingolimod nor natalizumab
have had a head to head comparison with high dose beta
interferon.
The population of beta interferon studies is different
from that of fingolimod and natalizumab (higher EDSS and
late MS/interferon group vs. lower EDSS and early
MS/other group).
All six approved medications differ in their efficacy rate
and for some studies of their long-term effects are still
lacking.
The longest assessment of any MS-specific treatment is
the 21-year long-term follow-up study with Betaferon
(interferon beta-1b). It provides the first strong survival
evidence for MS treatment, and further supports the
importance of starting patients as soon as possible on an
effective disease-modifying therapy with a favourable
safety profile in the long-term.
There is a strong body of clinical trial evidence that dose
and frequency of administration are important to achieve
optimal clinical benefit in MS. These data suggest that
higher dose and more frequent dosing of interferon beta
result in greater efficacy. This finding was confirmed by the
results of INCOMIN and EVIDENCE. Results from a pilot
study in patients with RRMS have indicated that increasing
the dose of IFNbeta-1b to 500 lg (16 MIU) had a more
pronounced biological effect compared with the standard
250 lg dose [17].
Therefore, we consider that there is overwhelming evi-
dence that high dose/high frequency betaferon is recom-
mended in RRMS, but the final decision is based on
agreement between the informed and educated patient and
the neurologist, in order to ensure long term patient com-
pliance and adherence to the treatment.
Primary progressive MS
At this time, there is no FDA-approved treatment for
PPMS. Research studies usually focus on medications for
the relapsing forms of MS. There have only been a handful
of treatment studies specifically for PPMS; the results so
far have not shown a significant treatment effect. The
standard FDA-approved medications for MS (interferons,
glatiramer acetate, mitoxantrone, natalizumab) have not
been proven useful in slowing the progression of PPMS.
We encourage people with PPMS to maintaining
mobility and fitness. In addition, there are medications
which may be used to treat symptoms such as bladder and
bowel urgency, erectile problems, spasticity, and pain, if
such treatments are needed.
Occasionally, intermittent (on and off) intravenous (IV)
steroids have been tried in patients with primary progres-
sive MS. Such therapies have provided only limited results
in these cases. Also, the chemotherapeutic drug metho-
trexate has been given in weekly oral doses to patients with
PPMS.
Assessing response to therapy
The group generally agreed that treatment response should
be evaluated at 6–12 months intervals depending on
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accessibility of MRI which differs from one country to
another. Poor response is defined by the presence of at least
two of the following:
1. One or more disabling relapses in the previous year
2. An active MRI as defined by the presence of two or
more new T2 W/Gd ? lesions
3. Sustained increase in EDSS by one step (for
EDSS B 5.5) or half a step for EDSS C 6.0.
In case of treatment non-response in RRMS, patients are
advised to switch from first line to second line agents. The
group generally classifies IFNb as first-line agents in view of
their well-established benefit/risk profiles over both the short
and the long-term. Most neurologists in our region follow the
EMA indication which recommends the use of natalizumab
and fingolimod as second-line agents in case of treatment
failure with IFNb [18]. Fingolimod was approved as a first-
line agent in the US, but there is still some reluctance to use it
as such in the Arabian Gulf region due to potential concerns
about its safety profile and lack of long term safety follow-
up. As mentioned previously, and based on clinical evidence
from the INCOMIN and EVIDENCE trials suggesting that
higher dose and more frequent dosing of IFNb results in
greater efficacy, the group considers moving a non-respon-
der patient on low dose interferon to high dose IFNb as an
appropriate option before escalation to second- line agents.
Duration of treatment
Knowing that there is no known cure for MS at this time,
beta interferon therapy should be maintained on a long
term basis in order to maintain the stability of the disease.
But if the patient is not responding to the treatment, we will
consider escalating therapy with the second line treatments.
Escalation therapy is considered when the patient sat-
isfies criteria for non-responders [19]. In this case, we
consider escalation therapy with the new therapies, the oral
fingolimod or the intravenous natalizumab.
Vitamin D supplement
More than 30 years have passed since vitamin D was origi-
nally hypothesized to be an important environmental deter-
minant of the prevalence of MS. During the three decades
following the initial linking of vitamin D and MS, evidence
has continued to mount. It is now known that MS occurs
more frequently in individuals with lower blood levels of
vitamin D. A study found that, compared to those with the
highest vitamin D blood levels, those with the lowest blood
levels were 62 % more likely to develop MS. A recent study
has quantified the impact of vitamin D blood levels on risk
for MS relapse—for each 4 ng/mL increase in 25-hydroxy
vitamin D in the blood; the risk for MS relapse is reduced by
12 %. In a randomized controlled trial, supplementation with
doses of vitamin D ranging from 10,000 to 40,000 IU daily
over the course of 52 weeks resulted in a reduction in
relapses and a reduction in the number of aggressive immune
cells in patients with MS [20].
We should not be surprised if vitamin D emerges as a
frontline treatment for MS in the coming years. However,
instead of waiting for mainstream physicians to begin
recommending vitamin D to MS patients, and being aware
of the high prevalence of vitamin D deficiency in our
region, we suggest that all MS patients monitor their blood
levels of 25-hydroxyvitamin D and maintain a blood level
of 50–80 ng/mL. The amount of supplementation required
to achieve this blood level varies from one person to
another, but it appears that many individuals require sup-
plementation of 5,000–8,000 IU of vitamin D each day to
reach these levels. Supplement with vitamin D may reduce
the risk of conversion from a first clinical event suggestive
of MS to clinical definite MS, as well as reduce the relapse
rate among patients with relapsing remitting MS.
Conclusion
Latest evidence from epidemiological studies have indi-
cated that the Arabian Gulf region has a high prevalence of
MS. Based on these facts we aim for a better MS awareness
in our region, and we look forward to patient education that
should be made by the neurologist and follow up by a
trained MS nurse in order to enhance patient’s adherence to
treatment and his/her quality of life.
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